130 related articles for article (PubMed ID: 25811109)
1. L-glutamine and whole protein restore first-phase insulin response and increase glucagon-like peptide-1 in type 2 diabetes patients.
Samocha-Bonet D; Chisholm DJ; Holst JJ; Greenfield JR
Nutrients; 2015 Mar; 7(4):2101-8. PubMed ID: 25811109
[TBL] [Abstract][Full Text] [Related]
2. Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients.
Samocha-Bonet D; Wong O; Synnott EL; Piyaratna N; Douglas A; Gribble FM; Holst JJ; Chisholm DJ; Greenfield JR
J Nutr; 2011 Jul; 141(7):1233-8. PubMed ID: 21593352
[TBL] [Abstract][Full Text] [Related]
3. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
5. Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes.
Alsalim W; Tura A; Pacini G; Omar B; Bizzotto R; Mari A; Ahrén B
Diabetes Obes Metab; 2016 Jan; 18(1):24-33. PubMed ID: 26354383
[TBL] [Abstract][Full Text] [Related]
6. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
Flint A; Kapitza C; Hindsberger C; Zdravkovic M
Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
[TBL] [Abstract][Full Text] [Related]
7. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
8. The insulinotropic effect of a high-protein nutrient preload is mediated by the increase of plasma amino acids in type 2 diabetes.
Tricò D; Frascerra S; Baldi S; Mengozzi A; Nesti L; Mari A; Natali A
Eur J Nutr; 2019 Sep; 58(6):2253-2261. PubMed ID: 30008106
[TBL] [Abstract][Full Text] [Related]
9. The effect of encapsulated glutamine on gut peptide secretion in human volunteers.
Meek CL; Lewis HB; Vergese B; Park A; Reimann F; Gribble F
Peptides; 2016 Mar; 77():38-46. PubMed ID: 26541888
[TBL] [Abstract][Full Text] [Related]
10. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
[TBL] [Abstract][Full Text] [Related]
11. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
12. Postprandial glucose, insulin and incretin responses to different carbohydrate tolerance tests.
Deng Y; Zhang Y; Zheng S; Hong J; Wang C; Liu T; Sun Z; Gu W; Gu Y; Shi J; Yao S; Wang W; Ning G
J Diabetes; 2015 Nov; 7(6):820-9. PubMed ID: 25395350
[TBL] [Abstract][Full Text] [Related]
13. COMPARISON OF THE LEVELS OF C-REACTIVE PROTEIN, GLP-1 AND GLP-2 AMONG INDIVIDUALS WITH DIABETES, MORBID OBESITY AND HEALTHY CONTROLS: AN EXPLORATORY STUDY.
Cazzo E; Pareja JC; Chaim EA; Coy CSR; Magro DO
Arq Gastroenterol; 2018; 55(1):72-77. PubMed ID: 29561982
[TBL] [Abstract][Full Text] [Related]
14. Does oral glutamine improve insulin sensitivity in adolescents with type 1 diabetes?
Torres-Santiago L; Mauras N; Hossain J; Weltman AL; Darmaun D
Nutrition; 2017 Feb; 34():1-6. PubMed ID: 28063503
[TBL] [Abstract][Full Text] [Related]
15. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects.
Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2011 Feb; 96(2):447-53. PubMed ID: 21047927
[TBL] [Abstract][Full Text] [Related]
16. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
[TBL] [Abstract][Full Text] [Related]
17. Postprandial glucose, insulin and glucagon-like peptide 1 responses to sucrose ingested with berries in healthy subjects.
Törrönen R; Sarkkinen E; Niskanen T; Tapola N; Kilpi K; Niskanen L
Br J Nutr; 2012 May; 107(10):1445-51. PubMed ID: 21929838
[TBL] [Abstract][Full Text] [Related]
18. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
19. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
[TBL] [Abstract][Full Text] [Related]
20. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]